Compare OLP & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLP | EMBC |
|---|---|---|
| Founded | 1982 | 1924 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 511.7M | 524.1M |
| IPO Year | 1995 | 2021 |
| Metric | OLP | EMBC |
|---|---|---|
| Price | $22.98 | $3.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $26.75 | $18.50 |
| AVG Volume (30 Days) | 40.1K | ★ 3.2M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 7.88% | 6.88% |
| EPS Growth | N/A | ★ 20.90 |
| EPS | 0.28 | ★ 0.67 |
| Revenue | ★ $82,740,000.00 | N/A |
| Revenue This Year | $11.98 | $1.17 |
| Revenue Next Year | $3.71 | N/A |
| P/E Ratio | $82.59 | ★ $4.54 |
| Revenue Growth | ★ 1.02 | N/A |
| 52 Week Low | $19.62 | $2.77 |
| 52 Week High | $25.90 | $15.55 |
| Indicator | OLP | EMBC |
|---|---|---|
| Relative Strength Index (RSI) | 52.52 | 16.88 |
| Support Level | $22.36 | N/A |
| Resistance Level | $23.61 | $9.51 |
| Average True Range (ATR) | 0.52 | 0.35 |
| MACD | -0.05 | -0.18 |
| Stochastic Oscillator | 55.56 | 4.28 |
One Liberty Properties Inc is a self-administered and self-managed real estate investment trust. It acquires, owns, and manages a geographically diversified portfolio consisting mainly of industrial and, to a lesser extent, retail properties, many of which are subject to long-term net leases. The trust has approximately one hundred and two properties located across several states in the United States of America. A majority of its revenue is generated in the form of rental income.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.